Compare Diageo plc (DEO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Sana Biotechnology Inc — how do they compare? Diageo plc trades at $94.95 (market cap $53.05B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Diageo plc is far larger — about 46.9× Sana Biotechnology Inc's market cap, and Diageo plc pays a 3.5% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DEO | SANA | |
|---|---|---|
Market Cap | $53.05B | $1.13B |
Sector | Technology | Health |
52-Week High | $115.33 | $5.92 |
52-Week Low | $72.47 | $2.68 |
Enterprise Value | $72.54B | $1.05B |
Dividend Yield | 3.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.96, down 3.24% today, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company reported FY2026 results with organic sales declining 2% but operating profit increasing 2% through cost savings. Recent news highlights a $1 billion cost-cutting plan and strategic reset under new CEO Dave Lewis, driving investor optimism despite North American weakness.
The outlook remains cautiously optimistic with analyst consensus leaning buy (49%) as cost savings and cash generation initiatives offset regional challenges. Key risks include persistent North American sales pressure and execution risks on the turnaround plan, while valuation metrics suggest premium pricing relative to historical levels.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
